Breast cancer recurrence risk could soon be estimated from a scan many patients already have. SimBioSys announced on October 15, 2026 that the U.S. Food and Drug Administration (FDA) has cleared TumorSight Risk through the 510(k) pathway. According to the company, it is the world’s first AI-powered, MRI-derived prognostic tool for breast cancer recurrence risk. It analyses routine breast MRI, pathology and clinical data to produce an individual prognosis at five and ten years.
What the breast cancer recurrence risk tool does
TumorSight Risk is meant for adult women with hormone receptor-positive (HR+), HER2-negative Stage I to IIIA breast cancer, a subtype the company says represents about 75 percent of all breast cancers in the U.S. It builds on the company’s earlier TumorSight Viz platform and applies what it calls spatial AI modelling to tumour features, surrounding tissue and clinical factors.
The cloud-based software produces a score from zero to 100 and a high, intermediate or low risk category. SimBioSys says it uses data already collected in routine care and needs no extra procedure, tissue shipment or special hardware, so results could be available before surgery. The company states the result should be considered alongside other clinicopathologic factors when assessing risk and planning care.
The validation data on recurrence risk
The clearance is supported by a blinded, prospectively designed retrospective study of 2,129 patients from Mayo Clinic, Emory University, Stanford Medicine and Mercy Medical Cedar Rapids. Results were recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. According to the company:
- Patients classed as high risk had a 3.3-fold greater risk of recurrence than those classed as low risk.
- Each 10-point rise in the score was linked to a 22 percent increase in relative recurrence risk.
- Estimated five-year recurrence risk ranged from 2.2 percent for the lowest scores (0 to 10) to 13.6 percent for the highest (58 to 100). At ten years, the range was 6.2 percent to 34.2 percent.
- The score stayed significantly associated with recurrence-free survival after adjusting for tumour and nodal stage, grade, age, race and treatment (p=0.002).
Where it could fit alongside existing tests
SimBioSys says current risk assessment often relies on clinicopathologic features and tissue-based genomic assays. These have advanced care, but the company notes that genomic testing can add cost, logistics and turnaround time. It positions the new tool as a complement, available earlier, that could help clinicians and patients weigh options such as chemotherapy and whether to continue endocrine therapy beyond five years.
Dr. Matthew Goetz of Mayo Clinic said the data show MRI-derived assessments “may provide prognostic information beyond standard clinicopathologic factors”. The release notes that Mayo Clinic has a financial interest in SimBioSys.
The other side: limits of the evidence
This is a company announcement, and “world’s first” is the company’s own description. The validation study was retrospective, even though it was designed prospectively and blinded, and the release does not describe how the tool performs in everyday clinics or whether it changes treatment decisions or patient outcomes. Risk groups are statistical: a “high-risk” score does not mean a particular patient’s cancer will return, and a “low-risk” score does not rule it out. The tool is cleared only for the specific subtype and stages named above.
As a security point, the software is cloud-based and the release does not explain how patient data is protected. This article is not medical advice; anyone with questions about their own risk should speak to their oncology team.
You may also like our stories on the Google AMIE medical chatbot clinic test and Agilent’s plan to buy digital pathology firm Proscia.
My view on breast cancer recurrence risk and AI
As a writer, I feel the idea is appealing: getting more information out of a scan that has already been done, without another test or a wait for lab results. Cautious readers will want independent studies in real clinics before leaning on a proprietary score. It is a notable regulatory step, but a beginning rather than a final answer.
FAQ: TumorSight Risk and breast cancer recurrence
What is TumorSight Risk?
It is FDA-cleared software from SimBioSys that analyses routine breast MRI, pathology and clinical data to give a 0 to 100 score and a high, intermediate or low category for recurrence risk at five and ten years.
Who is it for?
According to the company, it is intended for adult women with HR-positive, HER2-negative Stage I to IIIA breast cancer.
Does it replace genomic tests?
The company describes it as a complement to existing methods, not a replacement. Its result is meant to be considered alongside other clinical factors.